These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Thrombolysis after acute myocardial infarction: are Canadian physicians up to the challenge? Williams WL CMAJ; 1997 Feb; 156(4):509-11. PubMed ID: 9054820 [TBL] [Abstract][Full Text] [Related]
63. Comparison of the efficacy of pharmacoinvasive management for ST-segment elevation myocardial infarction in smokers versus non-smokers (from the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction). Tan NS; Goodman SG; Cantor WJ; Tan MK; Yan RT; Bagnall AJ; Mehta SR; Fitchett D; Strauss BH; Yan AT; Am J Cardiol; 2014 Oct; 114(7):955-61. PubMed ID: 25118119 [TBL] [Abstract][Full Text] [Related]
64. Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries. Cox JL; Lee E; Langer A; Armstrong PW; Naylor CD CMAJ; 1997 Feb; 156(4):497-505. PubMed ID: 9054819 [TBL] [Abstract][Full Text] [Related]
65. ST-segment analysis: a useful marker for reperfusion after thrombolysis with APSAC? The Belgian EMS Study Group. Bossaert L; Conraads V; Pintens H Eur Heart J; 1991 Mar; 12(3):357-62. PubMed ID: 2040318 [TBL] [Abstract][Full Text] [Related]
66. [Increased efficacy of thrombolytic therapy in acute myocardial infarction by improved properties of new thrombolytic agents]. Huber K Wien Klin Wochenschr; 2000 Sep; 112(17):742-8. PubMed ID: 11042902 [TBL] [Abstract][Full Text] [Related]
67. Double bolus of 0.75 MU streptokinase plus enoxaparin versus front-loaded alteplase plus unfractionated heparin in ST-segment elevation myocardial infarction. Tatu-Chiţoiu G; Teodorescu C; Dan M; Căpraru P; Guran M; Istrătescu O; Tatu-Chiţoiu A; Bumbu A; Dorobanţu M Rom J Intern Med; 2003; 41(4):395-408. PubMed ID: 15526522 [TBL] [Abstract][Full Text] [Related]
68. After coronary thrombolysis and reperfusion, what next? Bang NU; Wilhelm OG; Clayman MD J Am Coll Cardiol; 1989 Oct; 14(4):837-49. PubMed ID: 2677087 [TBL] [Abstract][Full Text] [Related]
69. Relationship between the door-to-TIMI-3 flow time and the infarct size in patients suffering from acute myocardial infarction: analysis based on the fibrinolysis and subsequent transluminal (FAST-3) trial. Watanabe K; Nagao K; Watanabe I; Kanmatsuse K Circ J; 2004 Apr; 68(4):280-5. PubMed ID: 15056821 [TBL] [Abstract][Full Text] [Related]
70. Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion. Wong CK; French JK; Krucoff MW; Gao W; Aylward PE; White HD Eur Heart J; 2002 Sep; 23(18):1449-55. PubMed ID: 12208225 [TBL] [Abstract][Full Text] [Related]
71. Comparison of the effects of streptokinase, t-PA and APSAC on human platelet aggregation in vitro in the absence and presence of aspirin. Fears R; Ferres H; Greenwood HC Thromb Res; 1990 Nov; 60(4):259-68. PubMed ID: 2128420 [TBL] [Abstract][Full Text] [Related]
73. Preliminary safety and tolerance data obtained in the comparative study of anisoylated plasminogen streptokinase activator complex versus heparin. Croydon EA Drugs; 1987; 33 Suppl 3():293-6. PubMed ID: 3315611 [TBL] [Abstract][Full Text] [Related]
74. Thrombolytic therapy in acute myocardial infarction. Paspa PA; Movahed A Am Fam Physician; 1992 Feb; 45(2):640-8. PubMed ID: 1739049 [TBL] [Abstract][Full Text] [Related]
75. [Thrombolysis in acute myocardial infarct]. Erne P Ther Umsch; 1991 Aug; 48(8):527-34. PubMed ID: 1926013 [TBL] [Abstract][Full Text] [Related]
76. Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. Gibson CM; Cannon CP; Piana RN; Breall JA; Sharaf B; Flatley M; Alexander B; Diver DJ; McCabe CH; Flaker GC J Am Coll Cardiol; 1995 Mar; 25(3):582-9. PubMed ID: 7860900 [TBL] [Abstract][Full Text] [Related]
77. Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators. Stone GW; Grines CL; Rothbaum D; Browne KF; O'Keefe J; Overlie PA; Donohue BC; Chelliah N; Vlietstra R; Catlin T; O'Neill WW J Am Coll Cardiol; 1997 Apr; 29(5):901-7. PubMed ID: 9120173 [TBL] [Abstract][Full Text] [Related]
78. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM; JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591 [TBL] [Abstract][Full Text] [Related]
79. A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Granger CB; White HD; Bates ER; Ohman EM; Califf RM Am J Cardiol; 1994 Dec; 74(12):1220-8. PubMed ID: 7977094 [TBL] [Abstract][Full Text] [Related]
80. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Bovill EG; Terrin ML; Stump DC; Berke AD; Frederick M; Collen D; Feit F; Gore JM; Hillis LD; Lambrew CT Ann Intern Med; 1991 Aug; 115(4):256-65. PubMed ID: 1906692 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]